A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

NCT03520491 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Bladder Cancer

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab
PROCEDURE: Radical cystectomy

Sponsor

Memorial Sloan Kettering Cancer Center